51454-63-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyano-pyridine-2-methanol is used as a key intermediate for the synthesis of various drugs, especially those that act on the central nervous system and cardiovascular system. Its unique chemical structure allows for the development of medications with specific therapeutic effects.
Used in Agrochemical Industry:
4-Cyano-pyridine-2-methanol is used as a building block in the manufacture of herbicides and insecticides. Its incorporation into these products enhances their effectiveness in controlling weeds and pests, contributing to improved agricultural yields and crop protection.

Upstream product

• 100-48-1 pyridine-4-carbonitrile 
• 67-56-1 methanol 
• 931-19-1 2-methylpyridine N-oxide 
• 2950-43-8 hydroxylamine-O-sulfonic acid 
• 7285-11-2 chloroform methanol 
• 7664-93-9 sulfuric acid 
• 30342-68-8 N-Ethoxy-2-picolinium iodide 
• 98549-84-9 4-Cyano-2-picoline-N-oxide 
• 2214-53-1 2-methyl-4-cyanopyridine 
• 51454-62-7 2-acetoxymethyl-isonicotinonitrile 
• 14906-59-3 4-cyanopyridine N-oxide 

Downstream Products

• 106474-82-2 4-cyano-2-(2-hydroxy)-ethylpyridine 
• 185220-30-8 2-(1'-hydroxyethyl)-4-acetylpyridine 
• 597563-02-5 2-(bromomethyl)isonicotinonitrile 
• 108337-75-3 2-(N-Benzyl-N-methylamino)ethyl Methyl 4-(4-Cyano-2-pyridyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate 
• 116308-38-4 4-Cyano-2-pyridinecarboxaldehyde 
• 1201448-11-4 C₁₈H₁₇N₃O₄ 
• 1201446-08-3 (4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)methanol 
• 1201446-41-4 N₁-((4-(5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl)pyridin-2-yl)methyl)-N₂,N₂-diethylethane-1,2-diamine 

Relevant academic research and scientific papers

KCNT1 INHIBITORS AND METHODS OF USE

The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

Hydroxymethylation of Quinolines with Na2S2O8 by a Radical Pathway

Quinolines and isoquinolines were treated with Na2S2O8 in a mixture of methanol and water at 70 °C to form hydroxymethylated quinolines and isoquinolines in good to moderate yields, under transition-metal-free conditions. The formed hydroxymethyl group was smoothly converted into aldehyde, ester, amide, bromomethyl, (N,N-diethylamino)methyl, cyano, and tetrazole groups, in good yields.

AROMATIC RING COMPOUND

Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.

OXIME COMPOUNDS AND THE USE THEREOF

The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO2, CRsu

4-HETEROARYLMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES

A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRx or CRxRy; if X=NRx then n is 1 or 2 and if X=CRxRy then n is 1; Rx is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; Ry is selected from H, hydroxy, amino; or Rx and Ry may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRxRy, RC1, RC2, Rx and Ry, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: (i) formula (i), where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; and (ii) formula (ii), where Q is O or S.

POTENTIATORS OF GLUTAMATE RECEPTORS

The present invention provides compounds of formula (I); pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.

Alpha-substituted pyrimidine-thioalkyl and alkylether compounds as inhibitors of viral reverse transcriptase

The subject invention relates to pyrimidine-thioalkyl and alkylether compounds of Formula (I) and pyrimidine-thioalkyl and alkylethers of Formula (IA), namely the compounds of Formula (I) where R 4 is selected from the group consisitng of --H or --NR 15 R 16 where R 15 is --H and R 16 is --H, C 1 -C 6 alkyl, NH 2 or R 15 and R 16 taken together with the --N form 1-pyrrolidino, 1-morpholino or 1-piperidino; and R 6 is selected from the group consisting of --H, or halo (preferably --Cl); with the overall proviso that R 4 and R 6 are not both --H. The compounds of Formula (IA) are useful in the treatment of individuals who are HIV positive being inhibitors of viral reverse transcriptase. STR1

Process for the selective mono-ortho-hydroxyalkylation of 4-substituted pyridine derivatives

A process is described for the selective mono-ortho-hydroxyalkylation of 4-substituted pyridine derivatives. In this case a nucleophilic hydroxyalkylation is carried out on the protonated pyridine derivative under the action of peroxodisulfate.